Research and Development

Solvotrin Therapeutics’ research and development strategy is focused on key technologies and diseases to better serve the needs of patients. The Company’s internal R&D division is organized to maximize flexibility and innovation. Solvotrin Therapeutics continues to build its product pipeline by identifying new drug targets.

Solvotrin Therapeutics has entered into a number of collaboration agreements with both public and private research organizations. To strengthen discovery research, the group has set up two types of alliances: technological partnerships (for access to new technologies) and product-based partnerships, which make it possible to explore new opportunities in Solvotrin’s spheres of excellence. The Company’s Scientific and Medical Advisory Board contributes to the R&D decision making process related to the portfolio and strategy.

Discovery of a “true” Aspirin Prodrug

The design of an aspirin ester prodrug capable of enzyme- mediated activation is one of the classical problems in prodrug chemistry.... Read the full article (PDF)

Isosorbide-based Aspirin Prodrugs

Aspirin prodrugs have been extensively investigated for many years as a means of depressing gastric toxicity (Jones, 1985) or increasing percutaneous absorption (e.g. Lofttsonet al., 1981).... Read the full article (PDF)

Isosorbide-based Aspirin Prodrugs: Integration of Nitric Oxide Releasing Groups

Aspirin is the world’s most widely used medicine. Some of its effects are due to its ability to trans-acetylate platelet cyclooxygenase-1 (COX-1a), resulting in effective abolition of platelet derived thromboxane A2 (TXA2), leading to cardio-vascular and cerebrovascular protection....
Read the full article (PDF)